Machine learning enables de novo multi-epitope design of plasmodium falciparum circumsporozoite protein to target trimeric L9 antibody
Nelson, J. A. D.; Garfinkle, S. E.; Lin, Z. J.; Park, J.; Kim, A. J.; Bayruns, K.; McCanna, M. E.; Konrath, K. M.; Agostino, C. J.; Kulp, D. W.; John, A. R. O.; Pallesen, J.
Show abstract
AbstractCurrently approved vaccines for the prevention of malaria provide only partial protection against disease, due to high variability in the quality of induced antibodies. These vaccines present the unstructured central repeat region, as well as the C-terminal domain, of the circumsporozoite protein (PfCSP) of the malaria parasite, Plasmodium falciparum (1). A recently discovered protective monoclonal antibody, L9, recognizes three structured copies of the PfCSP minor repeat. Similarly to other highly potent anti-malarial antibodies, L9 relies on critical homotypic interactions between antibodies for its high protective efficacy (2, 3). Here, we report the design of immunogens scaffolding one copy of PfCSPs minor repeat capable of binding L9. To design immunogens capable of presenting multiple, structure-based epitopes in one scaffold, we developed a machine-learning-driven structural immunogen design pipeline, MESODID, tailored to focus on multi-epitope vaccine targets. We use this pipeline to design multiple scaffolds that present three copies of the PfCSP minor repeat. A 3.6 [A] cryo-EM structure of our top design, minor repeat targeting immunogen (M-TIM), demonstrates that M-TIM successfully orients three copies of L9, effectively recapitulating its critical homotypic interactions. The wide prevalence of repeated epitopes in key vaccine targets, such as HIV-1 Envelope, SARS-CoV-2 spike, and Influenza Hemagglutinin, suggests that MESODID will have broad utility in creating immunogens that incorporate such epitopes, offering a new powerful approach to developing vaccines against a range of challenging infections, including malaria. Significance StatementIn this study, we present a machine learning driven, structure-guided protein design pipeline built specifically for the design of multi-epitope vaccine immunogens. We employ the pipeline here to design and solve the cryo-EM structure of a de novo immunogen that binds and properly orients three copies of the anti-malarial monoclonal antibody L9, producing a promising next-generation malaria vaccine immunogen. This design pipeline could be employed to design any number of structurally constrained multi-epitope immunogens, as well as other proteins designed to bind multiple targets.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- From sequence to scaffold: computational design of protein nanoparticle vaccines from AlphaFold2-predicted building blocks 97%
- Structure-based design of a soluble human cytomegalovirus glycoprotein B antigen stabilized in a prefusion-like conformation 96%
- Structural basis for surface activation of the classical complement cascade by the short pentraxin C-reactive protein 96%
Similar papers in this journal
- Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies 96%
- Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors 96%
- Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders 96%
Similar papers in this journal
- Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking 96%
- A human monoclonal antibody targeting a conserved pocket in the SARS-CoV-2 receptor-binding domain core 96%
- Structural insights into TRAP association with ribosome-Sec61 complex, and translocon inhibition by a CADA derivative 96%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.